Page 18 - Bio Developments News Today

Lumen Bioscience has been granted $16.2 million by the U.S. Department of Defense to advance its C. difficile infection (CDI) treatment.

Ultimovacs, a clinical-stage biotech developing novel immunotherapeutic cancer vaccines, has announced ‘encouraging’ overall survival (OS) data for its phase 1 clinical trial in malignant melanoma.

CellProthera is moving forward with its cell therapy which regenerates damaged tissue following a severe heart attack, restoring cardiac function and effectively mending a broken heart.

Terumo Blood and Cell Technologies, a medical tech company, and BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), are working together to demonstrate the capabilities of Terumo’s automated cell and gene therapy platforms to accelerate CAR-T cell development.

In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.

EXmoor pharma has opened the doors to its new cell and gene therapy centre GMP facility, based in Bristol, UK.

The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and EU, respectively.

Terumo Blood and Cell Technologies, a medical tech company, and BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), are working together to demonstrate the capabilities of Terumo’s automated cell and gene therapy platforms to accelerate CAR-T cell development.

OrganaBio, a contract technology development and manufacturing organization (CTDMO) specializing in solutions for cell and immunotherapy development, has launched a new division.

NextCell is a biotech company developing a novel treatment for type 1 diabetes, comprised of stem cells found in umbilical cords.